Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

CytoDyn Income from Continuous Operations 2010-2025 | CYDY

CytoDyn income from continuous operations from 2010 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
  
CytoDyn Annual Income from Continuous Operations
(Millions of US $)
2024 $-50
2023 $-80
2022 $-211
2021 $-176
2020 $-140
2019 $-56
2018 $-50
2017 $-26
2016 $-26
2015 $-25
2014 $-12
2013 $-10
2012 $-7
2011 $-4
2010 $-3
2009 $-2
CytoDyn Quarterly Income from Continuous Operations
(Millions of US $)
2025-02-28 $-5
2024-11-30 $-5
2024-08-31 $19
2024-05-31 $-17
2024-02-29
2023-11-30 $-10
2023-08-31 $-12
2023-05-31 $-19
2023-02-28 $-14
2022-11-30 $-26
2022-08-31 $-21
2022-05-31 $-84
2022-02-28 $-41
2021-11-30 $-40
2021-08-31 $-45
2021-05-31 $-65
2021-02-28 $-45
2020-11-30 $-35
2020-08-31 $-31
2020-05-31 $-73
2020-02-29 $-36
2019-11-30 $-15
2019-08-31 $-16
2019-05-31 $-15
2019-02-28 $-13
2018-11-30 $-14
2018-08-31 $-14
2018-05-31 $-10
2018-02-28 $-18
2017-11-30 $-11
2017-08-31 $-12
2017-05-31 $-7
2017-02-28 $-8
2016-11-30 $-5
2016-08-31 $-5
2016-05-31 $-6
2016-02-29 $-5
2015-11-30 $-5
2015-08-31 $-9
2015-05-31 $-14
2015-02-28 $-3
2014-11-30 $-5
2014-08-31 $-3
2014-05-31 $-3
2014-02-28 $-3
2013-11-30 $-4
2013-08-31 $-3
2013-05-31 $-2
2013-02-28 $-2
2012-11-30 $-2
2012-08-31 $-3
2012-05-31 $-3
2012-02-29 $-1
2011-11-30 $-1
2011-08-31 $-1
2011-05-31 $-1
2011-02-28 $-1
2010-11-30 $-1
2010-08-31 $-1
2010-05-31 $-2
2010-02-28 $-1
2009-11-30 $-1
2009-08-31 $0
2009-05-31 $0
2009-02-28 $0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.251B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $95.045B 37.51
Zoetis (ZTS) United States $66.334B 25.11
Takeda Pharmaceutical (TAK) Japan $46.806B 10.36
Daiichi Sankyo, - (DSNKY) Japan $41.678B 25.40
Summit Therapeutics (SMMT) United States $18.154B 0.00
Sandoz Group AG (SDZNY) Switzerland $17.706B 0.00
Merck (MKKGY) Germany $17.202B 14.23
Astellas Pharma (ALPMY) Japan $16.920B 11.99
Shionogi (SGIOY) Japan $14.087B 0.00
United Therapeutics (UTHR) United States $12.788B 11.57
Neurocrine Biosciences (NBIX) United States $10.030B 30.82
IPSEN (IPSEY) France $8.640B 0.00
Orion OYJ (ORINY) Finland $7.957B 22.55
Madrigal Pharmaceuticals (MDGL) United States $6.661B 0.00
Stevanato Group S.p.A (STVN) Italy $6.620B 42.04
Corcept Therapeutics (CORT) United States $6.567B 50.19
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.813B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.547B 11.36
Grifols, S.A (GRFS) Spain $4.868B 0.00
Ionis Pharmaceuticals (IONS) United States $4.515B 0.00
Soleno Therapeutics (SLNO) United States $3.209B 0.00
Crinetics Pharmaceuticals (CRNX) United States $2.831B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.747B 11.15
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.281B 14.15
Recursion Pharmaceuticals (RXRX) United States $2.211B 0.00
Hypermarcas (HYPMY) Brazil $2.128B 8.40
NewAmsterdam Pharma (NAMS) Netherlands $1.794B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.638B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.546B 0.00
Guardian Pharmacy Services (GRDN) United States $1.526B 0.00
ARS Pharmaceuticals (SPRY) United States $1.460B 186.00
Evotec AG (EVO) Germany $1.278B 0.00
Indivior (INDV) United States $1.242B 5.40
Ocular Therapeutix (OCUL) United States $1.162B 0.00
Ardelyx (ARDX) United States $1.148B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.064B 43.06
Dyne Therapeutics (DYN) United States $0.928B 0.00
AleAnna (ANNA) United States $0.878B 0.00
Collegium Pharmaceutical (COLL) United States $0.868B 4.61
Harrow (HROW) United States $0.855B 0.00
Enliven Therapeutics (ELVN) United States $0.810B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.776B 0.00
Xencor (XNCR) United States $0.683B 0.00
Cronos Group (CRON) Canada $0.682B 0.00
Bioventus (BVS) United States $0.641B 16.64
Xeris Biopharma Holdings (XERS) United States $0.633B 0.00
KalVista Pharmaceuticals (KALV) United States $0.597B 0.00
Organogenesis (ORGO) United States $0.535B 0.00
Savara (SVRA) United States $0.520B 0.00
Akebia Therapeutics (AKBA) United States $0.487B 0.00
Relay Therapeutics (RLAY) United States $0.456B 0.00
Elite Pharmaceuticals (ELTP) United States $0.450B 0.00
USANA Health Sciences (USNA) United States $0.448B 9.13
Theravance Biopharma (TBPH) Cayman Islands $0.431B 0.00
Siga Technologies (SIGA) United States $0.428B 7.30
Tourmaline Bio (TRML) United States $0.411B 0.00
Verve Therapeutics (VERV) United States $0.408B 0.00
Zevra Therapeutics (ZVRA) United States $0.387B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.353B 0.00
Altimmune (ALT) United States $0.350B 0.00
Oruka Therapeutics (ORKA) United States $0.345B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.301B 17.93
Heron Therapeutics (HRTX) United States $0.280B 0.00
Aquestive Therapeutics (AQST) United States $0.248B 0.00
Avita Medical (RCEL) United States $0.243B 0.00
ProKidney (PROK) United States $0.231B 0.00
OmniAb (OABI) United States $0.219B 0.00
Nature's Sunshine Products (NATR) United States $0.218B 25.70
Esperion Therapeutics (ESPR) United States $0.188B 23.75
MediWound (MDWD) Israel $0.185B 0.00
Wellgistics Health (WGRX) United States $0.171B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.164B 0.00
Nanobiotix S.A (NBTX) France $0.155B 0.00
Journey Medical (DERM) United States $0.144B 0.00
Profound Medical (PROF) Canada $0.144B 0.00
Protara Therapeutics (TARA) United States $0.143B 0.00
4D Molecular Therapeutics (FDMT) United States $0.142B 0.00
Inhibikase Therapeutics (IKT) United States $0.141B 0.00
Regulus Therapeutics (RGLS) United States $0.136B 0.00
Aldeyra Therapeutics (ALDX) United States $0.131B 0.00
Korro Bio (KRRO) United States $0.131B 0.00
Lyell Immunopharma (LYEL) United States $0.128B 0.00
Aclaris Therapeutics (ACRS) United States $0.123B 0.00
Larimar Therapeutics (LRMR) United States $0.122B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Nektar Therapeutics (NKTR) United States $0.118B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.118B 36.33
Champions Oncology (CSBR) United States $0.110B 18.11
Enanta Pharmaceuticals (ENTA) United States $0.109B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.101B 0.00
OptiNose (OPTN) United States $0.093B 0.00
Lexeo Therapeutics (LXEO) United States $0.090B 0.00
Galectin Therapeutics (GALT) United States $0.087B 0.00
Arch Biopartners (ACHFF) Canada $0.084B 0.00
Cardiol Therapeutics (CRDL) Canada $0.083B 0.00
ESSA Pharma (EPIX) Canada $0.079B 0.00
VAXART, INC (VXRT) United States $0.078B 0.00
Context Therapeutics (CNTX) United States $0.076B 0.00
Telomir Pharmaceuticals (TELO) United States $0.074B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.074B 0.00
Unicycive Therapeutics (UNCY) United States $0.072B 0.00
Cassava Sciences (SAVA) United States $0.070B 0.00
Achieve Life Sciences (ACHV) Canada $0.069B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.066B 0.00
Vivani Medical (VANI) United States $0.063B 0.00
Fractyl Health (GUTS) United States $0.060B 0.00
Pyxis Oncology (PYXS) United States $0.059B 0.00
Assertio Holdings (ASRT) United States $0.058B 0.00
Metagenomi (MGX) United States $0.057B 0.00
Acrivon Therapeutics (ACRV) United States $0.057B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.056B 0.00
Nutriband (NTRB) United States $0.056B 0.00
Inotiv (NOTV) United States $0.055B 0.00
PMV Pharmaceuticals (PMVP) United States $0.053B 0.00
Gain Therapeutics (GANX) United States $0.050B 0.00
Avalo Therapeutics (AVTX) United States $0.047B 0.00
Century Therapeutics (IPSC) United States $0.047B 0.00
Mural Oncology (MURA) Ireland $0.047B 0.00
Prelude Therapeutics (PRLD) United States $0.046B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.045B 0.00
Dominari Holdings (DOMH) United States $0.044B 0.00
ElectroCore (ECOR) United States $0.043B 0.00
Karyopharm Therapeutics (KPTI) United States $0.042B 0.00
Rafael Holdings (RFL) United States $0.042B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.037B 0.00
SCYNEXIS (SCYX) United States $0.035B 0.00
NRx Pharmaceuticals (NRXP) United States $0.033B 0.00
Surrozen (SRZN) United States $0.032B 0.00
FibroGen (FGEN) United States $0.029B 0.00
VYNE Therapeutics (VYNE) United States $0.028B 0.00
PolyPid (PYPD) Israel $0.028B 0.00
Tempest Therapeutics (TPST) United States $0.026B 0.00
CASI Pharmaceuticals (CASI) China $0.024B 0.00
DURECT (DRRX) United States $0.023B 0.00
Jupiter Neurosciences (JUNS) United States $0.021B 0.00
Enlivex Therapeutics (ENLV) Israel $0.018B 0.00
Mannatech (MTEX) United States $0.018B 7.14
Natural Alternatives (NAII) United States $0.017B 0.00
Lipocine (LPCN) United States $0.016B 0.00
BioVie (BIVI) United States $0.016B 0.00
GlycoMimetics (GLYC) United States $0.014B 0.00
Mangoceuticals (MGRX) United States $0.013B 0.00
MEI Pharma (MEIP) United States $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.013B 0.00
Vivos Therapeutics (VVOS) United States $0.012B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.012B 0.00
ProPhase Labs (PRPH) United States $0.012B 0.00
TherapeuticsMD (TXMD) United States $0.012B 0.00
Plus Therapeutics (PSTV) United States $0.011B 0.00
Minerva Neurosciences (NERV) United States $0.011B 8.42
Scienture Holdings (SCNX) United States $0.011B 0.00
Incannex Healthcare (IXHL) Australia $0.011B 0.00
Traws Pharma (TRAW) United States $0.010B 0.00
Biomerica (BMRA) United States $0.010B 0.00
Ernexa Therapeutics (ERNA) United States $0.010B 0.00
Relmada Therapeutics (RLMD) United States $0.010B 0.00
BioLineRx (BLRX) Israel $0.010B 0.00
Cosmos Health (COSM) United States $0.009B 0.00
Citius Pharmaceuticals (CTXR) United States $0.009B 0.00
Ainos (AIMD) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 2.68
Nuvilex (PMCB) United States $0.008B 0.00
Talphera (TLPH) United States $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Indaptus Therapeutics (INDP) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.005B 0.00
Klotho Neurosciences (KLTO) United States $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.004B 0.00
Conduit Pharmaceuticals (CDT) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Petros Pharmaceuticals (PTPI) United States $0.002B 0.00
CERo Therapeutics Holdings (CERO) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.001B 0.00
Heatwurx (PCSA) United States $0.001B 0.00
SHINECO (SISI) China $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Aditxt (ADTX) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00